US · Healthcare

Candel Therapeutics Inc (CADL)

Biotechnology

Candel Therapeutics Inc (CADL) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-19, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for CADL

P/E ratio

25.00

Candel Therapeutics Inc (CADL) — FAQ

What is CADL's P/E ratio?

The price-to-earnings (P/E) ratio for Candel Therapeutics Inc (CADL) is 25.00 (data as of 2026-05-19).

Does Candel Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Candel Therapeutics Inc (CADL). Check the MyAverix Finance app for the latest dividend data.

What sector is Candel Therapeutics Inc in?

Candel Therapeutics Inc (CADL) is classified in the Healthcare sector (Biotechnology industry).

What exchange is CADL listed on?

CADL is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)